Mumbai, April 30 -- The profit appears lower due to the exceptional gain that was recorded in Q4 FY25.

Total operating expenses for Q4 FY26 added up to Rs 144.06 crore, up 22.5% YoY.

Profit before tax in Q4 FY26 stood at Rs 40.20 crore, down by 70.2% from Rs 134.90 crore in Q4 FY25.

For FY26, the company posted net profit and revenue of Rs 115.17 crore (down 37.1% YoY) and Rs 707.52 crore (up 8.3% YoY), respectively.

The company said that in Q4, the Domestic Formulations (DF) business again delivered market-beating growth of 18.2%, compared to the Indian Pharma Market (IPM), which grew by 10.1% in the same period; a 1.8 times growth placing us significantly ahead of the market.

The API division demonstrated strong comeback and regist...